Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) ^{[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)}

Median PFS for High-Dose Melphalan?

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for High-Dose Melphalan? ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Comparison of the median PFS for High-Dose Melphalan with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for High-Dose Melphalan with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The impact of patient characteristics on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The role of genetic factors in the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The influence of previous treatments on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The correlation between the median PFS for High-Dose Melphalan and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for High-Dose Melphalan and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The role of supportive care in improving the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

The effect of concurrent health conditions on the median PFS for High-Dose Melphalan.

The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for High-Dose Melphalan. ### Response: The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from EVOMELA was None months with a 95% Confidence Interval (CI) of None ^{[1](https://www.astctjournal.org/article/S1083-8791(15)00574-1/fulltext)}

Median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)?

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Comparison of the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The impact of patient characteristics on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The role of genetic factors in the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The influence of previous treatments on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The effect of dosage and administration frequency on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The correlation between the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The role of supportive care in improving the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The effect of concurrent health conditions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Bortezomib+Dexamethasone (PVd) from OPTIMISMM was 11.2 months with a 95% Confidence Interval (CI) of (9.66, 13.73) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Median PFS for Bortezomib+Dexamethasone (Vd)?

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Bortezomib+Dexamethasone (Vd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Bortezomib+Dexamethasone (Vd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Bortezomib+Dexamethasone (Vd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from OPTIMISMM was 7.1 months with a 95% Confidence Interval (CI) of (5.88, 8.48) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30152-4/fulltext)}

Median PFS for Daratumumab 16 Mg/Kg?

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab 16 Mg/Kg? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Comparison of the median PFS for Daratumumab 16 Mg/Kg with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab 16 Mg/Kg with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The impact of patient characteristics on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The role of genetic factors in the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The influence of previous treatments on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The effect of dosage and administration frequency on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The correlation between the median PFS for Daratumumab 16 Mg/Kg and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab 16 Mg/Kg and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The role of supportive care in improving the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

The effect of concurrent health conditions on the median PFS for Daratumumab 16 Mg/Kg.

The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab 16 Mg/Kg. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab 16 Mg/Kg from SIRIUS was 3.7 months with a 95% Confidence Interval (CI) of (2.8, 4.6) ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext)}

Median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Comparison of the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The correlation between the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from POLLUX was 45.8 months with a 95% Confidence Interval (CI) of (34.1, NE) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Median PFS for Lenalidomide+Dexamethasone (Rd)?

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from POLLUX was 17.5 months with a 95% Confidence Interval (CI) of (13.9, 20.8) ^{[1](https://www.nature.com/articles/s41375-020-0711-6)}

Median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)?

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Comparison of the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The impact of patient characteristics on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The role of genetic factors in the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The influence of previous treatments on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The effect of dosage and administration frequency on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The correlation between the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The role of supportive care in improving the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

The effect of concurrent health conditions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) from CASTOR was 16.7 months with a 95% Confidence Interval (CI) of (12.3, NE) ^{[1](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32010-5/fulltext)}

Median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Comparison of the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The impact of patient characteristics on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The role of genetic factors in the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The influence of previous treatments on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The effect of dosage and administration frequency on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The correlation between the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The role of supportive care in improving the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The effect of concurrent health conditions on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).

The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) from ALCYONE was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Median PFS for Velcade Melphalan-Prednisone (VMP)?

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Velcade Melphalan-Prednisone (VMP)? ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Comparison of the median PFS for Velcade Melphalan-Prednisone (VMP) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Velcade Melphalan-Prednisone (VMP) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}